Gabather AB Sustainability Reports
Gabather AB is a Swedish clinical-stage biotechnology company focused on developing small-molecule therapeutics targeting the GABAA receptor system to treat central nervous system disorders such as schizophrenia, depression, and Alzheimer's disease.
Sector: Professional & technical services
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300VLUOMD0TE1O093
FIGI: BBG007F87547
10 reports from 2016 to 2025
